Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer

Tatjana Bilich(Deutschen Konsortium für Translationale Krebsforschung), Juliane S. Walz(Deutschen Konsortium für Translationale Krebsforschung)

Cancer Discovery

May 19, 2021

10.1158/2159-8290.cd-21-0191

Cited by 47

Related Papers

A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity

|Nature|2021|273

The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma

|Nature Communications|2022|73

Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma

|Blood Cancer Journal|2020|21

Impact of Mantle Cell Lymphoma Contamination of Autologous Stem Cell Grafts on Outcome after High-Dose Chemotherapy

|Cancers|2021|2